FDA pushes opioid education, page-3

Im not certain its a green light P, rather an acknowledgement by the FDA of the importance of opioids and that there are a raft of other methods that can be used to stem abuse before involving tighter distribution controls.

We might also start to benefit from improved investor sentiment for this area of medicine. On Friday the FDA missed the PDUFA date for Zogenix' Zohydro, the first pure hydrocodone painkiller. Zogenex' shares rose 55% after the delay was announced, an indication the market thinks the drug will be approved within weeks.

http://www.bloomberg.com/news/2013-02-27/zogenix-climbs-on-optimism-zohydro-pill-will-win-approval.html

Certainly we have improved volume over the last few days and doday we finally broke out of the 100c range. Lets see if this builds into something this week.